CJC-1295 + Ipamorelin (5mg/5mg) · Research brief

Does CJC-1295 Work? CJC 1295 Before and After Claims

Real Peptides Research TeamEditorial

Updated March 3, 20269 min read

56 WORDS

Short answer

Almost every cjc 1295 before and after photo circulating online measures something the published research never measured. The literature on CJC-1295 tracks two variables: circulating growth hormone and IGF-1. Photos track lighting, hydration, glycogen, posing, and the focal length of a phone camera. Those are not the same dataset, and they don't support the same conclusion.

Key takeaways

CJC-1295 is a DPP-4 resistant GHRH analog based on GRF(1-29); the DAC version binds albumin and carries a half-life measured in days, while the no-DAC form clears in roughly half an hour.
Teichman and colleagues (2006) documented multi-fold increases in mean growth hormone and IGF-1 in healthy adults after single doses, with IGF-1 remaining elevated for 9 to 11 days.
Ipamorelin is a selective GHS-R1a agonist characterized by Raun and colleagues (1998) as releasing GH without the cortisol and prolactin rises seen with GHRP-6.
Almost all cjc 1295 before and after material online is anecdotal, unblinded, uncontrolled, and confounded by concurrent diet and training changes.
Early visible change on any GH secretagogue is more consistent with sodium and water retention than with fat or lean tissue remodeling.
CJC-1295 and ipamorelin are not FDA-approved drugs; Real Peptides supplies both as research-grade compounds with batch certificates of analysis for laboratory work only.

We supply research-grade peptides to laboratories, so our team reads this question from the evidence side several times a week. What follows is what the literature reports, what forum reports structurally cannot report, and where the two quietly get merged.

Does CJC-1295 work?

CJC-1295 is a growth hormone-releasing hormone analog with documented endocrine activity in human volunteers. Research published in the Journal of Clinical Endocrinology and Metabolism found that single doses produced sustained, dose-dependent rises in mean growth hormone and IGF-1 lasting days. Whether that biomarker shift produces the visible changes shown in cjc 1295 before and after images is a separate, largely unstudied question.

The frequent error is treating an endocrine response as an outcome. Elevated IGF-1 is a biomarker change, not a body composition change, and no published controlled trial has followed the CJC-1295 plus ipamorelin pairing through to measured fat mass or lean mass endpoints. This piece covers the receptor mechanism, why progress photos fail as evidence, and the onset timelines the research does describe.

How CJC-1295 acts on the pituitary

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), built from GRF(1-29), the first 29 amino acids that carry GHRH's biological activity, with four amino acid substitutions that resist cleavage by dipeptidyl peptidase-4 (DPP-4), the enzyme that clears native GHRH within minutes.

Two forms exist and they behave very differently. The version with DAC (Drug Affinity Complex) carries a maleimidopropionic acid group that binds covalently to circulating albumin, stretching the half-life out to roughly a week. CJC-1295 no DAC, usually labeled modified GRF(1-29), clears in about half an hour.

The mechanism is straightforward: the molecule binds GHRH receptors on somatotroph cells in the anterior pituitary and increases growth hormone release. GH then acts on hepatocytes to stimulate production of IGF-1 (insulin-like growth factor 1). Researchers measure IGF-1 rather than GH because GH is secreted in pulses, and a single random GH draw tells you almost nothing.

The human data come from Teichman and colleagues (2006), who reported dose-dependent increases in mean GH concentrations of roughly 2 to 10 fold sustained for six days or more, IGF-1 increases of about 1.5 to 3 fold lasting 9 to 11 days, and a terminal half-life of 5.8 to 8.1 days in healthy adults.

So does cjc 1295 really work? At the receptor level, in a controlled setting, with a hormone assay as the endpoint, the response is documented. That is a far narrower claim than most people scrolling before-and-after threads believe they're getting. Neither compound is an FDA-approved drug, and both are supplied for laboratory research only.

Why progress photos measure the wrong variable

Growth hormone has a direct renal effect on sodium reabsorption and fluid balance. Visible change inside the first one to three weeks of any GH secretagogue protocol is far more consistent with fluid retention and glycogen shifts than with adipose or lean tissue remodeling, which moves on a scale of months. That single mechanism explains a large share of the most dramatic ipamorelin cjc 1295 before and after comparisons, and almost nobody posting them mentions it.

The cjc 1295 before and after reddit threads carry a structural problem no volume of photos can fix: self-selection. People who notice nothing post nothing. There's no control condition, no blinding, no DEXA scan, no standardized photography, and training, calories, sleep, and creatine status frequently all change in the same window.

The split by sex is telling. Cjc 1295 before and after male threads skew toward strength and recovery claims. Cjc 1295 before and after female threads, and the ipamorelin cjc 1295 before and after women discussions specifically, skew toward skin texture, sleep quality, and water retention complaints. Both categories are unverified, and baseline GH secretion differs meaningfully by sex and declines steadily with age, so identical inputs don't generate identical endocrine responses.

What would actually count as evidence: paired DEXA scans for fat and lean mass, fasting serum IGF-1 run on the same assay platform with an age-adjusted Z-score, standardized lighting and pose and time of day, and a documented intake log. Our team has yet to see a single forum post containing all four.

Ipamorelin, the combination, and realistic onset

Ipamorelin is a pentapeptide and a selective agonist at GHS-R1a, the growth hormone secretagogue receptor that also binds ghrelin. Raun and colleagues (1998), writing in the European Journal of Endocrinology, characterized it as the first selective GH secretagogue: it released growth hormone in their models without the accompanying ACTH, cortisol, and prolactin elevations seen with earlier compounds such as GHRP-6. Does ipamorelin really work? As a GH secretagogue in preclinical models, the effect is documented, and selectivity is the trait that distinguishes it.

The pairing rationale is receptor-based. A GHRH analog and a ghrelin-receptor agonist act through two separate pathways, and co-administration of GHRH with a secretagogue produces a larger GH pulse than either agent alone in endocrine research. That's a mechanistic argument, not proof of a physique result.

How long before cjc 1295 starts working? The GH response itself is near-immediate, on the order of minutes to hours. The IGF-1 elevation builds across days and, in the Teichman data, was still measurable 9 to 11 days after one administration. Forum timelines of six to twelve weeks are describing subjective, unmeasured change on a completely different clock.

One caveat researchers weigh: the DAC version holds GHRH signaling elevated continuously, which departs from the pulsatile rhythm the somatotropic axis normally runs on. Study designs examining pulsatile release typically use the no-DAC form for that reason. Is ipamorelin worth it as a research tool? Only if the endpoint you've chosen is one it can actually move. This is research education, not guidance for use in people or animals. Anyone with questions about growth hormone biology for themselves should raise them with a licensed physician, and anyone considering anything for an animal should talk to their veterinarian.

CJC 1295 Before and After: Anecdotal Reports vs Measured Endpoints

The table below sorts the four tiers of evidence people encounter when researching this compound, from weakest to strongest. What separates them isn't sincerity, it's whether anything was measured against a baseline.

Evidence tier	Typical claim window	What was actually measured	Main confounder	Bottom line
Forum progress photos and albums	4 to 12 weeks	Nothing quantified; lighting, posing, and hydration vary between shots	Diet and training almost always changed simultaneously	Useful as a hypothesis generator, worthless as an estimate of effect size
Self-reported sleep and recovery	First 1 to 2 weeks	Subjective rating only, no sleep staging or actigraphy	Expectancy effects are strongest on subjective endpoints	The most frequently reported and least verifiable category of all
User-posted IGF-1 lab panels	2 to 6 weeks	A real serum value, but usually one draw with no matched baseline	Assay platform differences between labs shift reference ranges	Closer to data, still uninterpretable without a pre-treatment value
Published endocrine studies	Hours to days post-administration	Mean GH concentration, serum IGF-1, half-life, hormone selectivity	Healthy volunteers, short duration, biomarker endpoints only	The only tier supporting a causal statement, and it stops at hormones

What If: Evaluating Peptide Outcome Claims

What if the only evidence I can find is forum photos?

Treat it as a signal about what to measure, not as a result. Anecdote is genuinely useful for generating research questions, which is why endocrine literature often follows community observation by years. The failure happens when a photo album gets cited as an effect size. If you want the measured version, the two papers linked above are the starting point, and both report hormones rather than body composition.

What if IGF-1 rises but nothing visible changes?

That outcome is entirely consistent with the published data. IGF-1 is a downstream biomarker of somatotroph stimulation, and raising it confirms the receptor pathway responded. It does not confirm that downstream tissue changed, because no controlled trial of this combination has tracked fat mass or lean mass to begin with. A biomarker moving is the study endpoint, not the user endpoint.

What if the report comes from a stack of four compounds at once?

Discard it for attribution purposes. When a GHRH analog, a secretagogue, a healing peptide, and a training block all start the same week, no single variable can be isolated, and this describes most of the more impressive peptide cjc 1295 before and after posts in circulation. Sequential single-variable designs are slow and unglamorous, which is exactly why almost nobody runs them informally.

What if a supplier can't produce a certificate of analysis for the batch?

The material is unverified, and any result obtained with it is unverified too. A certificate should identify the batch, report purity by HPLC, and confirm identity by mass spectrometry. Purity variance between suppliers is the single most overlooked confounder in informal peptide research, because a compound at 82% purity and one at 99% purity are not the same input even when the label matches.

The Unsatisfying Truth About Peptide Progress Photos

Here's the honest answer: there is no published before-and-after dataset for CJC-1295 or ipamorelin in the sense people are searching for. None. The human research measured hormones over days in healthy volunteers, and that's where it stopped. Everything visual you'll find is an uncontrolled n=1 with at least three uncontrolled variables running alongside it. That doesn't mean the compounds are inert, because the endocrine response is well documented. It means the question of what they do to a body over twelve weeks hasn't been answered by anyone, and photographs can't answer it retroactively.

Researchers sourcing material for this work can review our CJC-1295 no DAC and ipamorelin listings, the pre-measured CJC-1295 and ipamorelin blend, or the tesamorelin and ipamorelin stack. Background on each compound sits on our CJC-1295 and ipamorelin reference pages, batch documentation lives in our certificates of analysis, and the full catalog is in the shop.

The most useful thing anyone can do with a cjc 1295 before and after search is to notice what's missing from every result it returns. No baseline. No control. No measurement. A field that has produced precise half-life figures and hormone selectivity profiles has produced nothing resembling a controlled body composition endpoint for these two peptides, and that gap is the actual finding. Until someone runs that study, the photographs are documenting photography.

References

Peer-reviewed sources on CJC-1295 indexed in PubMed, listed for research context. Real Peptides supplies CJC-1295 for laboratory research use only.

Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. Substance use & misuse, 2016. PMID 26771670. doi:10.3109/10826084.2015.1082595
Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug testing and analysis, 2010. PMID 21204297. doi:10.1002/dta.233
Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 2009. PMID 19386527. doi:10.1016/j.ghir.2009.03.001
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of clinical endocrinology and metabolism, 2006. PMID 16352683. doi:10.1210/jc.2005-1536
Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American journal of physiology. Endocrinology and metabolism, 2006. PMID 16822960. doi:10.1152/ajpendo.00201.2006
Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of clinical endocrinology and metabolism, 2006. PMID 17018654. doi:10.1210/jc.2006-1702
Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, 2005. PMID 15817669. doi:10.1210/en.2004-1286

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Yes, as a growth hormone-releasing hormone analog with documented endocrine activity. Research in healthy adults reported dose-dependent multi-fold increases in mean growth hormone and IGF-1 after single administration. What has not been demonstrated in controlled human trials is any effect on measured body composition, which is the outcome most people are actually asking about.

At the receptor level, yes; the GHRH receptor response on pituitary somatotrophs is well characterized and reproducible. The skepticism is better aimed at the outcome claims than the mechanism. Elevated IGF-1 is a confirmed biomarker effect, while fat loss and muscle gain claims rest on uncontrolled anecdote rather than published endpoint data.

The growth hormone response begins within minutes to hours of administration, and serum IGF-1 climbs across the following days. In the 2006 human data, IGF-1 remained elevated for roughly 9 to 11 days after a single dose. Forum timelines of six to twelve weeks describe subjective impressions, not measured hormone kinetics.

As a growth hormone secretagogue, yes. Raun and colleagues characterized ipamorelin in 1998 as the first selective GHS-R1a agonist, releasing growth hormone without the ACTH, cortisol, and prolactin elevations produced by GHRP-6. Selectivity is the documented finding. Long-term human outcome data for body composition does not exist.

That depends entirely on the endpoint being studied. For research examining selective GH release without confounding cortisol or prolactin activity, ipamorelin is the better-characterized tool for that specific question. For anyone expecting the outcomes shown in progress photos, the supporting evidence simply has not been published.

No, and the reason is structural rather than about honesty. The cjc 1295 before and after reddit threads are self-selected, meaning null results are rarely posted, and they contain no control condition, no baseline measurement, and no standardized photography. Diet, training, sleep, and hydration typically change in the same period, making attribution impossible.

The DAC version carries a Drug Affinity Complex group that binds covalently to serum albumin, extending the half-life to roughly a week and holding GHRH signaling continuously elevated. CJC-1295 no DAC, also called modified GRF(1-29), clears in about half an hour and better preserves the natural pulsatile release pattern, which is why pulsatility studies generally use it.

Reported experiences differ, though none of it is measured data. Male threads skew toward strength and recovery claims, while ipamorelin cjc 1295 before and after women discussions skew toward skin, sleep, and water retention. Baseline growth hormone secretion does genuinely differ by sex and declines with age, so identical inputs would not be expected to produce identical endocrine responses.

These compounds are sold as research-use-only materials intended for qualified researchers, laboratories, and institutions. They are not FDA-approved drugs and are not sold for human or veterinary consumption. Regulatory status also varies by jurisdiction, and several growth hormone secretagogues have been flagged by the FDA as bulk substances raising safety questions for compounding.

Published work on GHRH analogs and secretagogues notes fluid retention from sodium reabsorption, injection site reactions, and potential effects on glucose handling and insulin sensitivity, since growth hormone is counter-regulatory to insulin. Long-term safety data for these specific compounds in humans is limited, and that absence of data is itself the important point.

Pricing varies widely by supplier, vial size, and purity grade, so comparing on price alone is misleading. Verification matters more: request a batch-specific certificate of analysis showing purity by HPLC and identity confirmation by mass spectrometry. Purity variance between suppliers is one of the largest uncontrolled variables in informal peptide research.

Lyophilized peptide powder is typically held frozen and protected from light and moisture, with the certificate of analysis specifying the manufacturer's conditions for that batch. Once a peptide is in solution, refrigerated storage and avoidance of repeated freeze-thaw cycles preserve integrity, because each cycle risks aggregation and loss of assay-verifiable potency.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA